Redmile Group LLC Sells 54,467 Shares of LivaNova PLC (NASDAQ:LIVN)

Redmile Group LLC trimmed its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 5.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 875,039 shares of the company’s stock after selling 54,467 shares during the quarter. LivaNova makes up 2.7% of Redmile Group LLC’s investment portfolio, making the stock its 15th largest position. Redmile Group LLC owned approximately 1.61% of LivaNova worth $45,975,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the business. Arizona State Retirement System lifted its holdings in LivaNova by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after buying an additional 299 shares during the period. Atria Investments Inc lifted its holdings in LivaNova by 6.2% in the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after buying an additional 331 shares during the period. Fifth Third Bancorp lifted its holdings in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after buying an additional 332 shares during the period. Hexagon Capital Partners LLC lifted its holdings in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after buying an additional 370 shares during the period. Finally, State of Alaska Department of Revenue lifted its holdings in LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after buying an additional 425 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

LIVN has been the subject of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. The Goldman Sachs Group started coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. Robert W. Baird raised their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $69.17.

LivaNova Stock Down 0.8 %

Shares of NASDAQ:LIVN opened at $51.19 on Thursday. The stock has a fifty day simple moving average of $52.28 and a two-hundred day simple moving average of $51.95. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of 121.88 and a beta of 0.98. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.